Medical Devices Startups

Augmedit develops augmented reality applications for surgical visualization and planning, helping surgeons improve procedural outcomes and reduce costs for healthcare institutions.

1 investor

Augmental develops body-coupled interfaces that enable hands-free control of computers and communication with AI, designed primarily for people with severe motor limitations. The company's products, MouthPad and VOX, provide cursor control and voice input respectively for individuals unable to use their hands.

1 investor

Augmented Hearing develops AI-powered speech enhancement technology that isolates and clarifies voice signals in noisy environments using deep learning and psychoacoustics. The company serves applications ranging from emergency communications to consumer audio devices.

1 investor

Augurex develops and commercializes diagnostic tests for autoimmune conditions, with a focus on reducing diagnostic delays and enabling timely patient care. The company's offerings include tests for rheumatoid arthritis and axial spondyloarthritis.

1 investor

August Bioservices is a contract research, development, and manufacturing organization (CDMO) specializing in sterile injectables, offering end-to-end services from development to commercial manufacturing. It serves pharmaceutical and biotech companies developing novel therapeutics.

1 investor

Aulea Medical develops single-use urological devices and platforms designed to reduce procedure time, post-operative hospitalization, and equipment complexity for treating conditions like benign prostatic hyperplasia and bladder tumors. The company serves hospitals and urology practices seeking to improve treatment efficiency and reduce infection risks associated with traditional reusable metal equipment.

1 investor

Auni Therapeutics develops immunotherapy treatments for food allergies, leveraging intralymphatic immunotherapy (ILIT) protocols and proprietary clinical innovations. The company serves patients with allergic disease and aims to bring next-generation allergen immunotherapies to market.

1 investor

IBSA offers pharmaceutical and medical products for assisted reproductive technology (ART) and fertility treatment, serving patients and couples undergoing in vitro fertilization and other fertility procedures. The company provides an integrated portfolio of medications and support services tailored to support the fertility journey.

1 investor

Aurabox is a platform enabling healthcare organisations to share medical imaging securely across organisational boundaries with partners, referrers, and patients. It aims to improve care coordination and clinical decision-making by facilitating seamless imaging exchange between healthcare providers.

1 investor

Aurealis Therapeutics is a Swiss-Finnish clinical-stage company developing multi-target bacterial gene therapies based on genetically engineered Lactococcus cremoris, using a modular platform that produces multiple human therapeutic proteins directly in diseased tissue. Its therapies target chronic wounds, cancer, and inflammatory diseases, with a lead product for diabetic foot ulcers.

1 investor

Aurelius Health operates a network of private hospitals and healthcare facilities across Malaysia, providing medical services and clinical care. The company manages multiple hospital locations and specializes in orthopedic, neuroscience, and general medical services.

1 investor

Aurenar develops a non-invasive, ear-worn neuromodulation wearable that stimulates a nerve in the ear to boost the body's natural control of inflammation, targeting complications in intensive care unit patients. The device aims to improve patient outcomes, reduce hospital length of stay, and lower the cost of ICU care.

1 investor

Auricle develops a neurostimulation implant designed to restore hearing for patients who do not benefit from hearing aids or existing solutions.

1 investor

Aurion Biotech develops regenerative cell therapies for ophthalmology, focused on treating blindness and vision loss from corneal endothelial disease. Its lead program, AURN001, is a combination therapy made from human donor endothelial cells intended to restore corneal clarity as an alternative to donor corneal transplantation.

1 investor

Aurora develops a platform for personalized gene editing to treat rare genetic diseases at scale. The company targets patients with rare disease variants by systematizing and scaling gene editing treatments to address genetic mutations that lack existing therapeutic options.

1 investor

AusBiotech is the national industry association representing Australia's life sciences ecosystem, advocating for policy, facilitating connections, and supporting growth for biotechnology, medical technologies, and digital health companies.

1 investor

Austrianova is a biotech company that manufactures cell-based products using encapsulation technology and GMP-grade processes. The company serves pharmaceutical and biotech firms developing cell therapies, with quality systems and data infrastructure based in Germany and Switzerland.

1 investor

AutoGenomics develops genetic testing platforms for clinical reference labs, specialty clinics, and hospital laboratories. The company's microarray technology enables multiplexed genetic marker detection and analysis for personalized medicine diagnostics.

1 investor

AutoIVF builds chip-based microfluidic systems that automate embryology steps in IVF laboratories, including its OvaReady product for oocyte preparation using a software-controlled instrument and single-use microfluidic kit. It targets IVF clinics and fertility labs, aiming to reduce operator variability and standardize laboratory workflows.

1 investor

AutonomUS develops technology to automate and standardize image-guided interventional medical procedures, aiming to make specialist interventional expertise available across settings from ERs and outpatient clinics to operating rooms and battlefield care. The company originated from a Department of Defense–supported collaboration between Massachusetts General Hospital physicians and MIT Lincoln Laboratory scientists.

1 investor

Aeris Biosciences (formerly Auxilium Health) develops biomaterials for regenerative medicine. The company is composed of scientists, engineers, and clinicians working in the human health field.

1 investor

Auxilius Pharma develops value-added cardiovascular medications by reformulating existing drugs into optimized dosage forms to improve patient outcomes. The company serves patients, healthcare providers, and payors by addressing unmet needs in cardiovascular health through enhanced drug delivery.

1 investor

Avails Medical develops the eQUANT™ System, an FDA-cleared diagnostic platform using electronic biosensor technology for rapid antimicrobial susceptibility testing in infectious disease care. The system targets hospitals and clinical laboratories to accelerate diagnosis of infections like sepsis and combat antimicrobial resistance.

1 investor

Avania is a clinical development and regulatory consulting firm that supports medical device companies through product development, clinical trial execution, and FDA regulatory submissions. The company serves medtech innovators navigating complex regulatory pathways from early-stage concept to market clearance.

1 investor